Search results
‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound...
Fox News· 4 hours agoResearchers may have hit "gold" when it comes to the treatment of multiple sclerosis. An...
...Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed...
WTNH-TV New Haven· 3 hours agoThe paper, lead...
Contineum Therapeutics shares coverage initiated with $25 PT by Morgan Stanley By Investing.com
Investing.com· 2 hours agoThe firm highlighted the biotechnology company's focus on developing treatments for neuroscience,...
Wayne State researcher receives grant from the National Multiple Sclerosis Society to explore new...
Newswise· 1 day agoThe three-year, $644,827 grant for his study, “Metabolic Stress and Oligodendrocyte...
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of...
Digital Journal· 2 hours ago(Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s ...
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks via Yahoo Finance· 6 days agoBiogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key...
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Proactive Investors· 2 hours agoImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the...
Immunic CMO details programs aimed at alleviating multiple sclerosis during UK's MS Awareness Week
Proactive Investors· 5 days agoImmunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the complexities of ...
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Reuters· 6 days ago, opens new tab beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series...
Vaccine Safety and DMT for Highly Active MS: New Data
Medscape· 6 days agoMany clinicians delay CD20 treatment until vaccine schedules are complete. A study suggests that this precaution may not be necessary.